Aktienanalyse zu Sensus Healthcare Inc (SRTS)SRTSSensus Healthcare Inc

Sensus Healthcare, Inc. is a medical device company. The Company is engaged in the development and delivery of non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is incorporated into a portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT technology is used to effectively and safely treat oncological and non-oncological skin conditions. The SRT-100 is a photon x-ray low-energy SRT system that provides patients with an alternative to surgery for treating NMSC, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with an SRT-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and comprehensive dosimetry parameters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Sensus Healthcare Inc is currently trading at $2.75, which is near its 52-week low of $2.66. However, the stock has shown a significant decline of 32.93% year-to-date and a 20.98% drop over the past year, indicating potential weakness. The RSI is at 34.59, suggesting it is nearing oversold territory, which could indicate a potential rebound. Despite recent insider buying activity, the company reported a widening net loss of $8.7 million in Q2 2026, which raises concerns about its financial stability. Therefore, while there may be a potential for recovery, the risks currently outweigh the rewards, making it prudent to hold rather than buy.

2 analysts cover SRTS: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.00.